論文

査読有り 国際誌
2011年8月

A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system.

Oncology reports
  • Kenji Zennami
  • Kazuhiro Yoshikawa
  • Eisaku Kondo
  • Kogenta Nakamura
  • Yoshiaki Upsilonamada
  • Marco A De Velasco
  • Motoyoshi Tanaka
  • Hirotsugu Uemura
  • Toru Shimazui
  • Hideyuki Akaza
  • Shinsuke Saga
  • Ryuzo Ueda
  • Nobuaki Honda
  • 全て表示

26
2
開始ページ
327
終了ページ
33
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3892/or.2011.1290

Molecular targeting agents have become formidable anticancer weapons showing much promise against refractory tumors and functional peptides and are among the more desirable of these nanobio-tools. Intracellular delivery of multiple functional peptides forms the basis for a potent, non-invasive mode of delivery, providing distinctive therapeutic advantages. We examine the growth suppression efficiency of human renal cell carcinoma (RCC) by single-peptide targeting. We simultaneously introduced p16INK4a tumor suppressor peptides by Wr-T-mediated peptide delivery. Wr-T-mediated transport of p16INK4a functional peptide into 10 RCC lines, lacking expression of the p16INK4a molecule, reversed the specific loss of p16 function, thereby drastically inhibiting tumor growth in all but 3 lines by >95% within the first 96 h. In vivo analysis using SK-RC-7 RCC xenografts in nude mice demonstrated tumor growth inhibition by the p16INK4a peptide alone, however, inoculation of Wr-T and the p16INK4a functional peptide mixture, via the heart resulted in complete tumor regression. Thus, restoration of tumor suppressor function with Wr-T peptide delivery represents a powerful approach, with mechanistic implications for the development of efficacious molecular targeting therapeutics against intractable RCC.

リンク情報
DOI
https://doi.org/10.3892/or.2011.1290
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/21567093
ID情報
  • DOI : 10.3892/or.2011.1290
  • PubMed ID : 21567093

エクスポート
BibTeX RIS